AXSOME THERAPEUTICS INC (AXSM) Stock Price & Overview
NASDAQ:AXSM • US05464T1043
The current stock price of AXSM is 160.49 USD. Today AXSM is down by -2.19%. In the past month the price decreased by -12.42%. In the past year, price increased by 34.3%.
AXSM Key Statistics
- Market Cap
- 8.209B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.69
- Dividend Yield
- N/A
AXSM Stock Performance
AXSM Stock Chart
AXSM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AXSM. When comparing the yearly performance of all stocks, AXSM is one of the better performing stocks in the market, outperforming 81.13% of all stocks.
AXSM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AXSM. AXSM may be in some trouble as it scores bad on both profitability and health.
AXSM Earnings
On February 23, 2026 AXSM reported an EPS of -0.56 and a revenue of 196.00M. The company beat EPS expectations (17.97% surprise) and missed revenue expectations (-0.49% surprise).
AXSM Forecast & Estimates
26 analysts have analysed AXSM and the average price target is 223.66 USD. This implies a price increase of 39.36% is expected in the next year compared to the current price of 160.49.
For the next year, analysts expect an EPS growth of 81.24% and a revenue growth 56.04% for AXSM
AXSM Groups
Sector & Classification
AXSM Financial Highlights
Over the last trailing twelve months AXSM reported a non-GAAP Earnings per Share(EPS) of -3.69. The EPS increased by 38.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.55% | ||
| ROE | -207.46% | ||
| Debt/Equity | 2.17 |
AXSM Ownership
AXSM Latest News, Press Relases and Analysis
AXSM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.07 | 948.755B | ||
| JNJ | JOHNSON & JOHNSON | 20.37 | 591.001B | ||
| MRK | MERCK & CO. INC. | 21.39 | 298.537B | ||
| PFE | PFIZER INC | 8.82 | 151.354B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 126.888B | ||
| ZTS | ZOETIS INC | 17.87 | 55.509B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.74 | 27.378B | ||
| VTRS | VIATRIS INC | 5.78 | 16.937B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.53 | 12.151B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.67B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.517B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 4.459B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AXSM
Company Profile
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The firm's commercial products include Auvelity, Sunosi and Symbravo. The company is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Company Info
AXSOME THERAPEUTICS INC
One World Trade Center, 29Th Floor
New York City NEW YORK 10038 US
CEO: Herriot Tabuteau
Employees: 925
Phone: 12123323241
AXSOME THERAPEUTICS INC / AXSM FAQ
What does AXSM do?
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The firm's commercial products include Auvelity, Sunosi and Symbravo. The company is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Can you provide the latest stock price for AXSOME THERAPEUTICS INC?
The current stock price of AXSM is 160.49 USD. The price decreased by -2.19% in the last trading session.
Does AXSOME THERAPEUTICS INC pay dividends?
AXSM does not pay a dividend.
What is the ChartMill technical and fundamental rating of AXSM stock?
AXSM has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for AXSOME THERAPEUTICS INC?
The Revenue of AXSOME THERAPEUTICS INC (AXSM) is expected to grow by 56.04% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for AXSOME THERAPEUTICS INC?
AXSOME THERAPEUTICS INC (AXSM) has a market capitalization of 8.21B USD. This makes AXSM a Mid Cap stock.